Protein shedding in urothelial bladder cancer: prognostic implications of soluble urinary EGFR and EpCAM

• Published in: British journal of cancer Vol. 112; no. 6; pp. 1052 - 1058
• Main Authors: Bryan, R T, Regan, H L, Pirrie, S J, Devall, A J, Cheng, K K, Zeegers, M P, James, N D, Knowles, M A, Ward, D G
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 17.03.2015; Nature Publishing Group
• Subjects: 631/61/475; 692/53/2422; 692/699/67/589/1336; Aged; Aged, 80 and over; Antigens, Neoplasm - urine; Biomarkers, Tumor - urine; Biomedical and Life Sciences; Biomedicine; Bladder cancer; Cancer Research; Case-Control Studies; Cell Adhesion Molecules - urine; Cell Line, Tumor; Drug Resistance; Epidemiology; Epithelial Cell Adhesion Molecule; Female; Humans; Male; Molecular Diagnostics; Molecular Medicine; Oncology; Prognosis; Receptor, Epidermal Growth Factor - urine; Urinary Bladder Neoplasms - diagnosis; Urinary Bladder Neoplasms - urine; EpCAM; urine; prognosis; bladder cancer; EGFR

Background: Better biomarkers must be found to develop clinically useful urine tests for bladder cancer. Proteomics can be used to identify the proteins released by cancer cell lines and generate candidate markers for developing such tests. Methods: We used shotgun proteomics to identify proteins re...